T1D Exchange is helping vTv Therapeutics find participants for their clinical trial evaluating a drug called cadisegliatin (also known as TTP399). TTP399 is an investigational oral medication that supports the liver’s ability to store glucose, which may help reduce the risk of hypoglycemia (low blood sugar) and lower A1C levels.
New study locations have been added across the U.S., making participation easier. If you live near one of the study site locations, you may now be eligible for this clinical trial, even if you were previously disqualified. Check out the site directory to see if there is a study site near you.
About the Investigational Drug
The study drug, called cadisegliatin, or TTP399, is an investigational medication for adults living with T1D. TTP399 is an oral medication designed to support the liver in more effectively storing glucose. This may help reduce the risk of hypoglycemia and lower your A1C.
WHAT TO EXPECT IF YOU ENROLL IN THE CLINICAL TRIAL
Participants in this clinical trial will be assigned at random to one of three groups. Two groups will receive TTP399 at different dosages. One group will receive a placebo. You will not be told which of the three groups to which you have been assigned. All participants will receive insulin. Each group will take their assigned study medication for 26 weeks. Participants must take the assigned study drug twice daily at mealtimes. Participants will also be provided with a Dexcom G7 CGM to wear throughout the trial.
Your participation in the study is expected to last approximately 9 months and requires up to 11 in-person and 11 virtual visits.
The clinical trial research staff will communicate other requirements.
Qualified participants will receive payment for time and travel.
